

6 May 2008

IS Pharma plc ('IS Pharma' or the 'Group')

Notification of Interest

The Group was notified on 2 May 2008 in a letter dated 30 April 2008 that Barclays PLC, through Barclays Stockbrokers Ltd and Gerrard Investment Management Ltd, has a notifiable interest of 1,539,321 ordinary shares of 70 pence each in IS Pharma. This is equivalent to 5.01% of the issued share capital of the Group.

The issued share capital of the Group is 30,754,404 ordinary shares of 70 pence per share.

- ENDS -

Enquiries:

Financial Dynamics Limited
Billy Clegg / Edward Westropp

Tel: +44(0) 20 7831 3113

Noble & Company Limited
Matthew Hall / Sam Reynolds

Tel: +44(0) 20 7763 2200

IS Pharma plc
Tim Wright – CEO
www.ispharma.plc.uk

Tel: +44(0) 1244 625150

About IS Pharma plc (AIM:ISPH):

The Group focuses on building a late-stage pharmaceutical and medical devices business in the specialist hospital medicine sector. Based in the UK, IS Pharma commercialises its portfolio in the UK directly while also consolidating its presence in the major European markets through a strong network of distributors.

Currently focused in the areas of critical care, neurology and oncology, the Group's marketed and development brands include:

- Critical Care: Volplex®, (plasma substitute); Cryogesic® / Dermogesic®, (cryo-analgesic); Haemopressin®, (treatment of oesophageal varices); and ISOplex®, (isotonic plasma substitute); AquiHex® (anti bacterial)
- Neurology: Mysoline® (primidone), a product currently used to treat epilepsy and which IS Pharma is developing for management of Essential Tremor, a distressing

- condition affecting an estimated 1 in 25 over 40 year olds for which primidone is one of only two recommended treatments; Acoranil® (antidepressant syrup)
- Oncology: Cryogestic®, 5 FU, (an oral chemotherapeutic agent for the treatment of cancer); and most recently, Aloxi® (treatment of chemotherapy induced nausea and vomiting).

Following the acquisition of Speciality European Pharma International AG, in April 2008, IS Pharma adopted a new name (IS Pharma plc) and acquired a portfolio of specialist hospital pharmaceutical products and importantly the international rights for the critical care drug, Haemopressin (IS Pharma previously held rights for Haemopressin in the UK and Ireland).

Products which are outside of the Group's core hospital focus or which are in early stage of research are out-licensed, including the successful OptiFlo™ Catheter Maintenance Solutions (to Bard Limited) and micelle nanotechnology, which is incorporated into an early stage lidocaine based product for the treatment of interstitial cystitis (to Plethora Solutions Limited). To find out more please go to www.ispharma.plc.uk.

OptiFlo™ is a trademark of C.R. Bard Inc or an affiliate